<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39330902</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Tropical medicine and infectious disease</Title><ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Replacement Therapy with Blood Products in People Living with HIV.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">213</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed9090213</ELocationID><Abstract><AbstractText>Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to determine the frequency of cytopenias and coagulation deficiencies in PLWH as well as the need for replacement therapy with blood products. We sought to determine whether there is an association between severe anemia or thrombocytopenia (requiring replacement therapy) and CD4+T lymphocyte levels. All 29 patients were critically ill, with 27 out of 29 (93%) in advanced stages of HIV disease and 23 out of 29 (79%) having CD4+ lymphocyte counts below 200 cells/microL. Most patients were either late presenters (45%) or had been lost to follow-up (41%). In addition to HIV infection, various conditions that could alter hematologic parameters were associated, including co-infections with hepatitis viruses, tuberculosis at various sites, malignant diseases, sepsis, SARS-CoV-2 infection, or other opportunistic infections. No significant correlation was found between severe anemia or severe thrombocytopenia or coagulation deficiencies and the CD4+T lymphocyte count. Our data suggest that these hematological disorders in patients with advanced HIV infection are more likely to be associated comorbidities rather than the HIV infection per se.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olariu</LastName><ForeName>Mihaela Cristina</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-3442-2338</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Bals" National Institute of Infectious Diseases, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iancu</LastName><ForeName>Mihaela Adela</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-2881-878X</Identifier><AffiliationInfo><Affiliation>Department of Internal, Family and Occupational Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olariu</LastName><ForeName>Mihai Hristu</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>"Matei Bals" National Institute of Infectious Diseases, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aramă</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Bals" National Institute of Infectious Diseases, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simoiu</LastName><ForeName>Mădălina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Bals" National Institute of Infectious Diseases, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruceru</LastName><ForeName>Miruna Maria</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>"Matei Bals" National Institute of Infectious Diseases, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbu</LastName><ForeName>Ecaterina Constanta</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0001-9560-6264</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balanescu</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal, Family and Occupational Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Romania Clinical Research Unit RECIF (Reseau d'Epidemiologie Clinique International Francophone), 020125 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>"Matei Bals" National Institute of Infectious Diseases, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Trop Med Infect Dis</MedlineTA><NlmUniqueID>101709042</NlmUniqueID><ISSNLinking>2414-6366</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD4+T lymphocyte count</Keyword><Keyword MajorTopicYN="N">HIV infection</Keyword><Keyword MajorTopicYN="N">anemia</Keyword><Keyword MajorTopicYN="N">thrombocytopenia</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39330902</ArticleId><ArticleId IdType="pmc">PMC11436115</ArticleId><ArticleId IdType="doi">10.3390/tropicalmed9090213</ArticleId><ArticleId IdType="pii">tropicalmed9090213</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Choi S.Y., Kim I., Kim N.J., Lee S.-A., Choi Y.-A., Bae J.-Y., Kwon J.H., Choe P.G., Park W.B., Yoon S.-S., et al. Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia. Korean J. Hematol. 2011;46:253–257. doi: 10.5045/kjh.2011.46.4.253.</Citation><ArticleIdList><ArticleId IdType="doi">10.5045/kjh.2011.46.4.253</ArticleId><ArticleId IdType="pmc">PMC3259517</ArticleId><ArticleId IdType="pubmed">22259631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyeyune R., Saathoff E., Ezeamama A., Löscher T., Fawzi W., Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect. Dis. 2014;14:496. doi: 10.1186/1471-2334-14-496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-496</ArticleId><ArticleId IdType="pmc">PMC4165997</ArticleId><ArticleId IdType="pubmed">25209550</ArticleId></ArticleIdList></Reference><Reference><Citation>Volberding P.A., Levine A.M., Dieterich D., Mildvan D., Mitsuyasu R., Saag M., Anemia in HIV Working Group Anemia in HIV infection: Clinical impact and evidence-based management strategies. Clin. Infect. Dis. 2004;38:1454–1463. doi: 10.1086/383031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/383031</ArticleId><ArticleId IdType="pubmed">15156485</ArticleId></ArticleIdList></Reference><Reference><Citation>Olariu C., Nurciu A., Vasilescu I., Stanescu A.M.A., Dobre C., Sticlaru L., Olariu M. Afectarea măduvei hematogene la pacienții cu infecție HIV. Rom. J. Med. Pract. 2018;13:160–161. doi: 10.37897/rjmp.2018.2.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.37897/rjmp.2018.2.15</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchionatti A., Parisi M.M. Anemia and thrombocytopenia in people living with HIV/AIDS: A narrative literature review. Int. Health. 2021;13:98–109. doi: 10.1093/inthealth/ihaa036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/inthealth/ihaa036</ArticleId><ArticleId IdType="pmc">PMC7902680</ArticleId><ArticleId IdType="pubmed">32623456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortel T., Federman D. Street Drugs: Emerging Hematologic Complications of Illicit Drug Us; Proceedings of the 61st ASH Annual Meeting; Orlando, FL, USA. 7–10 December 2019.</Citation></Reference><Reference><Citation>World Health Organization  WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. ISBN: 9789241595629.  [(accessed on 2 September 2024)].  Available online:  https://iris.who.int/handle/10665/43699.</Citation></Reference><Reference><Citation>World Health Organization  Worldwide Prevalence of Anaemia 1993–2005. 2020.  [(accessed on 15 July 2024)].  ISBN: 9789241596657. Available online:  https://www.who.int/publications/i/item/9789241596657.</Citation></Reference><Reference><Citation>Bosch N.A., Law A.C., Bor J., Myers L.C., Roubinian N.H., Liu V.X., Walkey A.J. Red Blood Cell Transfusion at a Hemoglobin Threshold of 7 g/dl in Critically Ill Patients: A Regression Discontinuity Study. Ann. Am. Thorac. Soc. 2022;19:1177–1184. doi: 10.1513/AnnalsATS.202109-1078OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202109-1078OC</ArticleId><ArticleId IdType="pmc">PMC9278636</ArticleId><ArticleId IdType="pubmed">35119978</ArticleId></ArticleIdList></Reference><Reference><Citation>Izak M., Bussel J.B. Management of thrombocytopenia. F1000Prime Rep. 2014;6:45. doi: 10.12703/P6-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.12703/P6-45</ArticleId><ArticleId IdType="pmc">PMC4047949</ArticleId><ArticleId IdType="pubmed">24991422</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson D.R., Albert M., Heels-Ansdell D., Arnold D.M., Lauzier F., Zarychanski R., Crowther M., Warkentin T.E., Dodek P., Cade J., et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: Frequency, risk factors, and outcomes. Chest. 2013;144:1207–1215. doi: 10.1378/chest.13-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.13-0121</ArticleId><ArticleId IdType="pubmed">23788287</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N. Engl. J. Med. 2002;346:995–1008. doi: 10.1056/NEJMra010501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra010501</ArticleId><ArticleId IdType="pubmed">11919310</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori A., Coenen T., Costagiola D., Dedes N., Ellefson M., Gatell J., Girardi E., Johnson M., Kirk O., Lundgren J., et al. Late presentation of HIV infection: A consensus definition. HIV Med. 2011;12:61–64. doi: 10.1111/j.1468-1293.2010.00857.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1293.2010.00857.x</ArticleId><ArticleId IdType="pubmed">20561080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocroft A., Lundgren J.D., Sabin M.L., Monforte A.D., Brockmeyer N., Casabona J., Castagna A., Costagliola D., Dabis F., De Wit S., et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the collaboration of observational HIV epidemiological research Europe study (COHERE) PLoS Med. 2013;10:e1001510. doi: 10.1371/journal.pmed.1001510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001510</ArticleId><ArticleId IdType="pmc">PMC3796947</ArticleId><ArticleId IdType="pubmed">24137103</ArticleId></ArticleIdList></Reference><Reference><Citation>Krentz H., Auld M., Gill M. The high cost of medical care for patients who present late (CD4 &lt; 200 cells/μL) with HIV infection. HIV Med. 2004;5:93–98. doi: 10.1111/j.1468-1293.2004.00193.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1293.2004.00193.x</ArticleId><ArticleId IdType="pubmed">15012648</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S., Ninkovic J., Banerjee S., Charboneau R.G., Das S., Dutta R., Kirchner V.A., Koodie L., Ma J., Meng J., et al. Opioid Drug Abuse and Modulation of Immune Function: Consequences in the Susceptibility to Opportunistic Infections. J. Neuroimmune Pharmacol. 2011;6:442–465. doi: 10.1007/s11481-011-9292-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-011-9292-5</ArticleId><ArticleId IdType="pmc">PMC3601186</ArticleId><ArticleId IdType="pubmed">21789507</ArticleId></ArticleIdList></Reference><Reference><Citation>Plein L.M., Rittner H.L. Opioids and the Immune System–Friend or Foe. Br. J. Pharmacol. 2017;175:2717–2725. doi: 10.1111/bph.13750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13750</ArticleId><ArticleId IdType="pmc">PMC6016673</ArticleId><ArticleId IdType="pubmed">28213891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronald P.J., Robertson J.R., Elton R.A. Continued Drug Use and Other Cofactors for Progression to AIDS among Injecting Drug Users. AIDS. 1994;8:339–344. doi: 10.1097/00002030-199403000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-199403000-00007</ArticleId><ArticleId IdType="pubmed">7913328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas G.M., Griswold M., Gebo K.A., Keruly J., Chaisson R.E., Moore R.D. Illicit Drug Use and HIV-1 Disease Progression: A Longitudinal Study in the Era of Highly Active Antiretroviral Therapy. Am. J. Epidemiol. 2006;163:412–420. doi: 10.1093/aje/kwj059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwj059</ArticleId><ArticleId IdType="pubmed">16394200</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores J., Liang Y., Ketchum N.S., Turner B.J., Bullock D., Villarreal R., Potter J.S., Taylor B.S. Prescription Opioid Use is Associated with Virologic Failure in People Living with HIV. AIDS Behav. 2018;22:1323–1328. doi: 10.1007/s10461-017-1842-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-017-1842-2</ArticleId><ArticleId IdType="pubmed">28688032</ArticleId></ArticleIdList></Reference><Reference><Citation>Basukala B., Rossi S., Bendiks S., Gnatienko N., Patts G., Krupitsky E., Lioznov D., So-Armah K., Sagar M., Cheng C., et al. Virally Suppressed People Living with HIV Who Use Opioids Have Diminished Latency Reversal. Viruses. 2023;15:415. doi: 10.3390/v15020415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020415</ArticleId><ArticleId IdType="pmc">PMC9961149</ArticleId><ArticleId IdType="pubmed">36851631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E., Hogg R.S., Lima V.D., Kerr T., Yip B., Marshall B.D.L., Montaner J.S.G. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550–554. doi: 10.1001/jama.300.5.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.300.5.550</ArticleId><ArticleId IdType="pubmed">18677027</ArticleId></ArticleIdList></Reference><Reference><Citation>Re M.C., Zauli G., Furlini G., Giovannini M., La Placa M. HIV-1 infection and hematologic picture. Microbiologica. 1991;14:165–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">1857267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibellini D., Clo A., Morini S., Miserocchi A., Ponti C., Re M.C. Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J. Virol. 2013;2:91–101. doi: 10.5501/wjv.v2.i2.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v2.i2.91</ArticleId><ArticleId IdType="pmc">PMC3785048</ArticleId><ArticleId IdType="pubmed">24175233</ArticleId></ArticleIdList></Reference><Reference><Citation>Assefa M., Abegaz W.E., Shewamare A., Medhin G., Belay M. Prevalence and correlates of anemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia. BMC Hematol. 2015;15:6. doi: 10.1186/s12878-015-0024-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12878-015-0024-6</ArticleId><ArticleId IdType="pmc">PMC4455710</ArticleId><ArticleId IdType="pubmed">26045966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gedefaw L., Yemane T., Sahlemariam Z., Yilma D. Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: A comparative study. PLoS ONE. 2013;8:e72202. doi: 10.1371/journal.pone.0072202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072202</ArticleId><ArticleId IdType="pmc">PMC3745448</ArticleId><ArticleId IdType="pubmed">23977253</ArticleId></ArticleIdList></Reference><Reference><Citation>Agegnehu C.D., Merid M.W., Yenit M.K. Predictors of Anemia among Adult HIV Positive Patients on First-Line Antiretroviral Therapy in Northwest Ethiopia: A Retrospective Follow-Up Study. HIV/AIDS-Res. Palliat. Care. 2021;13:455–466. doi: 10.2147/HIV.S280338.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/HIV.S280338</ArticleId><ArticleId IdType="pmc">PMC8096420</ArticleId><ArticleId IdType="pubmed">33958896</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishnu P., Aboulafia D.M. Haematological manifestations of human immune deficiency virus infection. Br. J. Haematol. 2015;171:695–709. doi: 10.1111/bjh.13783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13783</ArticleId><ArticleId IdType="pubmed">26452169</ArticleId></ArticleIdList></Reference><Reference><Citation>Assinger A. Platelets and infection—An emerging role of platelets in viral infection. Front. Immunol. 2014;5:649. doi: 10.3389/fimmu.2014.00649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00649</ArticleId><ArticleId IdType="pmc">PMC4270245</ArticleId><ArticleId IdType="pubmed">25566260</ArticleId></ArticleIdList></Reference><Reference><Citation>Olariu M., Olariu C., Olteanu D. Thrombocytopenia in chronic hepatitis C. J. Gastrointestin. Liver Dis. 2010;19:381–385.</Citation><ArticleIdList><ArticleId IdType="pubmed">21188328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelariu A.-C., Coman A.E., Lionte C., Gorciac V., Sorodoc V., Haliga R.E., Petris O.R., Bologa C., Puha G., Stoica A., et al. The Value of Early and Follow-Up Elevated Scores Based on Peripheral Complete Blood Cell Count for Predicting Adverse Outcomes in COVID-19 Patients. J. Pers. Med. 2022;12:2037. doi: 10.3390/jpm12122037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12122037</ArticleId><ArticleId IdType="pmc">PMC9781715</ArticleId><ArticleId IdType="pubmed">36556258</ArticleId></ArticleIdList></Reference><Reference><Citation>Manaças L.R.A., de Amorim R.L.O., Aguila A., Novo P.C., Badin R.C. Evaluation of hematological changes and immune response biomarkers as a prognostic factor in critical patients with COVID-19. PLoS ONE. 2024;19:e0297490. doi: 10.1371/journal.pone.0297490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0297490</ArticleId><ArticleId IdType="pmc">PMC10903867</ArticleId><ArticleId IdType="pubmed">38421951</ArticleId></ArticleIdList></Reference><Reference><Citation>Arildsen H., Sørensen K., Ingerslev J., Østergaard L., Laursen A. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med. 2013;14:1–9. doi: 10.1111/j.1468-1293.2012.01027.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1293.2012.01027.x</ArticleId><ArticleId IdType="pubmed">22639788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayne E.S., Louw S.J. Good Fences Make Good Neighbors: Human Immunodeficiency Virus and Vascular Disease. Open Forum Infect. Dis. 2019;6:ofz303. doi: 10.1093/ofid/ofz303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz303</ArticleId><ArticleId IdType="pmc">PMC6847507</ArticleId><ArticleId IdType="pubmed">31737735</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins M.V., Joseph S.B., Dittmer D.P., Mackman N. Cardiovascular Disease and Thrombosis in HIV Infection. Arter. Thromb. Vasc. Biol. 2023;43:175–191. doi: 10.1161/ATVBAHA.122.318232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.122.318232</ArticleId><ArticleId IdType="pmc">PMC10165851</ArticleId><ArticleId IdType="pubmed">36453273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>